Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atovaquone and Azithromycin Combination Therapy in COVID-19
NCT04339426Phase 2Terminated
- Sponsor
- HonorHealth Research Institute
- Start
- Apr 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atovaquone and azithromycin in coronavirus disease 2019 (COVID-19), sponsored by HonorHealth Research Institute. Primary endpoint: Virology Cure Rate at 10 days. Started Apr 2020; status: terminated.
02
Drugs
atovaquoneazithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04339426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339426.